This week we rethink what we know about GLP-1s (again), including what it might mean for people with schizophrenia.
An Exploration of Their Emerging Role in Psychiatry
A growing body of research suggests that glucagon-like peptide-1 receptor agonists might have therapeutic potential in psychiatric and addictive disorders.
Recent studies suggest that GLP-1s (including exenatide, liraglutide, semaglutide, and dulaglutide) have shown neuroprotective, anti-inflammatory, and mood-stabilizing effects in preclinical models.
Animal studies (and early human trials) have hinted that GLP-1s could curb both depressive and anxiety symptoms, particularly in Parkinson’s disease. Some have even suggested that it might boost cognitive performance in Alzheimer’s patients and patients living with major depressive disorder.
Even so, the results remain mixed. And the authors insist that more rigorous studies could offers some clarification.
In addiction research, GLP-1 agonists have shown the ability to curb alcohol intake and reduce binge drinking in both animals and humans, likely by modulating reward-related brain circuits. One study even linked GLP-1 use to fewer alcohol-related hospital events.
Despite these encouraging results, their effect on other substances, such as cocaine, appears less consistent. While dulaglutide has shown some anxiolytic potential, other GLP-1s haven’t done much to ease anxiety symptoms in clinical trials.
These early findings offer a compelling case for further research into GLP-1s as possible adjuncts in psychiatric care.
IN OTHER PSYCHIATRY AND NEUROLOGY NEWS
- The Journal of Clinical Psychiatry covers GLP-1s, too, with a case study that describes use of the drug in a patient with schizophrenia and severe, olanzapine-induced weight gain.
- A PCC report describes a case in which cocaine-induced cardiac toxicity initially masked β-blocker (carvedilol) toxicity.
- The latest ASCP Corner helps clinicians better understand the practical issues involved in the use of xanomeline-trospium and its entry into the pharmacopoeia for schizophrenia.
- A new international study reveals some sobering truths about how doctors really feel about assisted suicide.
- And don’t miss the latest installment of our series looking at “Emerging Approaches in Schizophrenia.”
